Regeneron Pharmaceuticals Reports Q3 Earnings Beat with $5.1 Billion in Revenue
Regeneron Pharmaceuticals (REGN) reported strong third-quarter financial results, significantly exceeding analyst expectations for both earnings and revenue. The company posted a Non-GAAP earnings per share (EPS) of $20.07, surpassing estimates by $3.82, while total revenue reached $5.1 billion. The revenue figure represents a substantial 36% increase compared to the same period last year, beating consensus estimates by approximately $540 million. This growth underscores strong commercial performance and market momentum for the company's product portfolio.
Tickers: $REGN